Top

Reactions Weekly

Published in:

01-02-2024 | Osimertinib | Case report

Gefitinib/Immune-globulin/Osimertinib

Lack of efficacy, keratitis and toxic epidermolysis necrotizing disease

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Xu Y, et al. Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review. [Review] Current Drug Safety 19 : 309-312, No. 2, Jan 2024. Available from: URL: https://dx.doi.org/10.2174/1574886318666230529123200

Title: Gefitinib/Immune-globulin/Osimertinib
Lack of efficacy, keratitis and toxic epidermolysis necrotizing disease
Publication date: 01-02-2024
Publisher: Springer International Publishing
Keywords: Osimertinib
Gefitinib
Metastasis
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-53000-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gefitinib/Immune-globulin/Osimertinib

Lack of efficacy, keratitis and toxic epidermolysis necrotizing disease

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Flurbiprofen

Mitomycin

Epinephrine

Adalimumab/Amoxicillin/clavulanic-acid

Nivolumab

Elasomeran